PONVORY® (ponesimod)
PONVORY® WAS PROVEN SUPERIOR AT REDUCING RELAPSES* AND LESIONS† VS AUBAGIO® IN A STUDY LASTING ~2 YEARS
HELPING CONTROL MS TODAY
MAKING PLANS FOR TOMORROW
HELPING CONTROL MS TODAY
MAKING PLANS FOR TOMORROW
HELPING CONTROL MS TODAY
MAKING PLANS FOR TOMORROW
HELPING CONTROL MS TODAY
MAKING PLANS FOR TOMORROW
PONVORY®
Proven to help control the symptoms and signs of relapsing MS in adults
SUPERIOR at reducing relapses* and the number of new and enlarging lesions† vs a proven oral therapy (Aubagio®)
Unlike an injection or infusion, PONVORY® is an oral, once-daily pill that is discreet and can be taken anywhere. Most people can take their first dose at home‡
*PONVORY® was shown to reduce the average number of relapses per year.
†PONVORY® was shown to reduce the average number of new gadolinium-enhancing (GdE) T1 and new or enlarging T2 lesions.
‡Most people take their first dose of PONVORY® at home, but first-dose monitoring is required for people with certain cardiac conditions (slow heart rate, certain types of heart block, and heart attack or heart failure occurring >6 months prior to treatment initiation and in stable condition). Supervision of this first dose should take place in a healthcare setting.
Approved by the FDA for relapsing MS
PONVORY® is part of a group of MS medicines called disease-modifying therapies (DMTs).
Get the conversation started
Explore resources that can help you talk to your healthcare professional about PONVORY®.
Ready to begin your treatment journey with PONVORY®?
See what’s ahead.
Explore available savings options
Interested in cost support?
Your story could help others
